louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01996878: Genetic Polymorphism and Parkinson's Disease in Taiwanese
Official title: Association Analysis of Single Nucleotide Polymorphisms and the Incidence of Parkinson's Disease in a Hospital-based Case-control Study in Taiwan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson's Disease
Keywords: Parkinson's disease
Genetic Polymorphism
Lead sponsor: Changhua Christian Hospital
Sponsor class: OTHER
First posted: 2013-11-27
Enrollment: 334
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Taiwanese

Brief summary: To observe and analyze the correlation between Single Nucleotide polymorphisms (SNPs) and the incidence of Parkinson's disease in Taiwanese.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Parkinson's disease (case subjects are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)
* Healthy volunteers without Parkinson's disease

Exclusion Criteria:

* Cases showing atypical features, including multiple system atrophy and progressive supranuclear gaze palsy, or secondary causes of Parkinsonism, such as neuroleptic drugs, infection, tumor, previous cerebrovascular accident and known toxins

Primary outcomes:
measure: single nucleotide polymorphisms in certain candidate genes
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chang-Hua
country: Taiwan
facility: Department of Neurology, Chang-Hua Christian Hospital
Study officials:
affiliation: Chang Hua Christian Hospital
name: Shey-Lin Wu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00832078: Test Catheter Pilot Study in Healthy Volunteers
Official title: Test Catheter Pilot Study in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Coloplast A/S
Sponsor class: INDUSTRY
First posted: 2009-01-29
Enrollment: 28
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety of an intermittent catheter in comparison with an already existing catheter on the market. The study is a randomised, single blinded, cross-over study including 25 healthy males.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Male
* Signed informed consent
* Negative urine multistix

Exclusion Criteria:

* Abnormalities, diseases or surgical procedures performed in the lower urinary tract

Primary outcomes:
measure: Discomfort
timeFrame: After each catheterisation
Secondary outcomes:
measure: Handling
timeFrame: After each catheterisation
measure: Preference
timeFrame: At study termination
measure: Haematuria
timeFrame: After each catheterisation
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshopsitalet
state: København Ø
Study officials:
References:
Clinical trial NCT04613778: Correction of Breech Presentation With Laser Acupuncture
Official title: Correction of Breech Presentation With Laser Acupuncture: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breech Presentation
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2020-11-03
Enrollment: 30
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acupuncture-type interventions (such as moxibustion and acupuncture) at Bladder 67 (BL67, Zhiyin point) have been proposed to have positive effects on breech presentation. However, the role of laser acupuncture for Breech presentation remains unknown. The aim of this study is to evaluate the effectiveness and safety of laser acupuncture in correcting breech presentation.


Eligibility criteria: Inclusion Criteria:

* breech presentation or non-cephalic presentation
* gestation age 28\~34 weeks
* singleton

Exclusion Criteria:

* uterus anomaly
* uterus tumors
* risk of preterm labor

Primary outcomes:
measure: Cephalic presentation at gestation age (GA) of 36 weeks
timeFrame: at gestation age (GA) 36 weeks
Secondary outcomes:
measure: Cephalic presentation at labor
timeFrame: numbers of cephalic presentation at labor (an average of GA 38 weeks)
Other outcomes:
measure: adverse events
timeFrame: through study completion, an average of 6 weeks
measure: preterm labor
timeFrame: through study completion, an average of 6 weeks
measure: methods of delivery
timeFrame: at labor, an average of GA 38 weeks
Locations:
city: Keelung
country: Taiwan
facility: Chang Gung Memorial Hospital
Study officials:
References:
Clinical trial NCT01098578: Floseal Treatment for Posterior Epistaxis Study
Official title: Floseal Posterior Epistaxis Pilot Study (PEPIS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epistaxis
Keywords: Posterior Epistaxis
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2010-04-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Effectiveness of Floseal for the treatment of posterior epistaxis.

Detailed description: Floseal, a hemostatic agent, is an effective treatment for anterior epistaxis as well as numerous other acute bleeding conditions throughout the body. The investigators hypothesize that Floseal is an effective treatment for posterior epistaxis. If so, then this will also lead to significant cost savings in comparison to any other method of treatment of posterior epistaxis. The investigators have planned a prospective, nonblinded, nonrandomised study with a total of 40 subjects with posterior epistaxis to be included in this study.

Eligibility criteria: Inclusion Criteria:

* age greater than 18 years of age
* posterior epistaxis

Exclusion Criteria:

* patients with anterior epistaxis
* known sensitivity to any of the materials of Floseal or the topical medications administered as part of the evaluation and treatment of epistaxis (lidocaine, xylometazoline hydrochloride)
* pregnant or breast feeding woman

Primary outcomes:
measure: Effectiveness of Floseal for the Treatment of Posterior Epistaxis.
timeFrame: Immediate effect with 1 hour observation and follow-up at 5 and 30 days following treatment.
Secondary outcomes:
measure: Cost Savings of Floseal Treatment in Comparison to Posterior Packing, Surgical, and Embolisation Treatments for Posterior Epistaxis.
timeFrame: 30 days
Other outcomes:
measure: Total Institutional Cost Savings
timeFrame: End of study. Cost calculated after 20 patients were treated with Floseal
Locations:
Study officials:
affiliation: Ottawa Hospital Research Institute
name: Shaun Kilty, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kilty SJ, Al-Hajry M, Al-Mutairi D, Bonaparte JP, Duval M, Hwang E, Tse D. Prospective clinical trial of gelatin-thrombin matrix as first line treatment of posterior epistaxis. Laryngoscope. 2014 Jan;124(1):38-42. doi: 10.1002/lary.24240. Epub 2013 Jun 28.
Clinical trial NCT03099278: Ezetimibe for Patients With Chronic Hepatitis D
Official title: Ezetimibe for Patients With Chronic Hepatitis D
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Chronic Hepatitis D
Keywords: hepatitis D
Ezetimibe
HDV RNA
Lead sponsor: Ziauddin Hospital
Sponsor class: OTHER
First posted: 2017-04-04
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with Ezetimibe may lead to decline in hepatitis D virus levels. The aim of the study is to evaluate the utility of Ezetimibe in patients with chronic HDV infection


Eligibility criteria: Inclusion Criteria:

* Treatment experienced patients; non-responders of relapsers of pegylated interferon therapy
* Age 18 years or above
* Presence of anti-HDV in serum
* Presence of quantifiable HDV RNA in serum
* Elevated ALT \> ULN

Exclusion Criteria:

* Decompensated liver disease
* Patients with ALT levels greater than 10 times ULN (400 U/L)
* Pregnancy or inability to practice adequate contraception.
* Significant systemic or major illnesses other than liver disease, including, but not limited to, congestive heart failure, renal failure (eGFR\<50 ml/min), organ transplantation, serious psychiatric disease or depression and active coronary artery disease.
* Systemic immunosuppressive therapy
* Evidence of another form of liver disease in addition to viral hepatitis
* Active substance abuse, such as alcohol or injection drugs
* Hepatocellular carcinoma
* Concurrent hepatitis C infection or HIV coinfection
* Diagnosis of malignancy in the five years
* Concurrent usage of statins
* Concurrent use of any other drug known to inhibit NTCP
* Inability to understand or sign informed consent
* Any other condition, which in the opinion of the investigators would impede the patient's participation or compliance in the study

Primary outcomes:
measure: • Decline of HDV RNA quantitative measurements of >1 logs from baseline
timeFrame: 12 weeks of therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Ziauddin University Hospital
state: Sindh
Study officials:
References:
Clinical trial NCT01391078: Comparison of Sensimed Triggerfish With Goldmann Applanation Tonometry and Perkins Tonometry
Official title: Comparison of Sensimed Triggerfish (TF) 24 Hour IOP Monitoring With Goldmann Applanation Tonometry (GAT) and Perkins Tonometry in Glaucoma Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Primary Open Angle Glaucoma
Keywords: glaucoma
IOP
Sensimed Triggerfish
Goldmann Applanation Tonometry
fluctuation
comparison
Lead sponsor: Johannes Gutenberg University Mainz
Sponsor class: OTHER
Collaborators: name: Sensimed AG
First posted: 2011-07-11
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: This prospective, crossover study is designed to correlate SENSIMED Triggerfish® (TF) continuous IOP monitoring with conventional 24 h intraocular pressure profiles in glaucoma patients. There are two control measurements: The GAT/Perkins profile in the same eye in the second night and the GAT/Perkins profile in the same night in the fellow eye. Therefore, each eye serves as test eye and also as control for the second test eye.


Eligibility criteria: Inclusion Criteria:

* Patient is able to comply with the study procedure
* Patient must be ≥ 18 years old
* Diagnosis of primary open angle glaucoma (EGS criteria)
* Similar behaviour of IOP in both eyes in former IOP profiles
* Patient has consented to be in the trial and signed informed consent is available before any study related procedures are carried out
* Visual Acuity of 20/200 or better in both eyes
* Ability of subject to understand the character and individual consequences of the study
* For women with childbearing potential, adequate contraception

Exclusion Criteria:

Primary outcomes:
measure: Relation of GAT/Perkins with TF in a cross-over regression analysis.
timeFrame: 48 hours
Secondary outcomes:
measure: Correlation of IOP in the test eye (TF) compared to a conventional 24h IOP profile (GAT) the reference eye (same night)
timeFrame: 48 hours
measure: Correlation of IOP profile (GAT) right versus left eye
timeFrame: 48 hours
measure: Correlation of IOP profile (TF) right versus left eye
timeFrame: 48 hours
measure: Correlation of IOP with blood pressure
timeFrame: 48 hours
measure: Correlation of IOP with heart rate
timeFrame: 48 hours
Other outcomes:
Locations:
city: Mainz
country: Germany
facility: Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University Mainz
state: RLP
Study officials:
References:
Clinical trial NCT06675578: Treatment of Periodontitis Stage II by Tulsi Gel
Official title: Comparative Study Between the Efficiency of Tulsi Gel and Chlorohexidine Gel As Locally Administered Medication Agents Used in the Treatment of Stage II Periodontitis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Periodontitis, Stage II
Keywords: stage II periodontitis
periodontitis
clinical attachment loss
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2024-11-05
Enrollment: 24
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will be carried out to compare between the effect of 4%Tulsi gel and 1%Chlorohexidine gel as locally administered agents in the treatment of stage II periodontitis. Clinical parameters measurements, microbiological and radiographic assessment will be performed at base line, one month and 3 months after the intervention.


Eligibility criteria: Inclusion Criteria:

* All patients included in this study will be having Stage II Periodontitis
* Aging from 30 to 50 years old
* Free from any local or systemic risk factors that may affect the results of the study.

Exclusion Criteria:

* Long-term therapy with medications within a month prior to enrollment that could affect periodontal status or healing.
* Pregnant woman and lactating mothers.
* Patients with previous periodontal treatment including scaling and root planning and periodontal surgery in the last 3 and 6 months, respectively.

Primary outcomes:
measure: Clinical parameters
timeFrame: 3 months after end of treatment
measure: Clinical parameters
timeFrame: 3 months after end of treatment
measure: Clinical parameters
timeFrame: 3 months after end of treatment
Secondary outcomes:
measure: Microbiological assessment
timeFrame: 3 months after end of treatment
measure: Microbiological assessment
timeFrame: 3 months after end of treatment
measure: Microbiological assessment
timeFrame: 3 months after end of treatment
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry, Al-Azhar university
Study officials:
References:
Clinical trial NCT02996071: May Preoperative Waist to Height Ratio Predict Postoperative Weight Loss in Bariatric Patients?
Official title: May Preoperative Waist to Height Ratio Predict Postoperative Weight Loss in Bariatric Patients?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bariatric Surgery Candidate
Obesity, Morbid
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2016-12-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Bariatric surgery is an effective method for treatment of obesity. Sleeve gastrectomy is one of surgical methods and became popular in recent years. Weight loss rates after bariatric surgery differs among patients. The exact reason of this difference stays unclear. age, nationality, difference between body composition and type of surgery may be in concern. waist to height ratio has become popular recent years as an indicator of cardiomethabolic status. in this study, investigation of the effect of waist to height ratio differences of patients on weight loss following laparoscopic sleeve gastrectomy as a bariatric surgery.

Detailed description: Waist to height raito is the major determinator of patients and will be noted in every patient who will fulfil the eligibility criteras defined below and undergo laparoscopic sleeve gastrectomy. demographic data, BMI, body lipid composition, lean body weight also will be noted. all patients will undergo standardized laparoscopic sleeve gastrectomy operation. patients will be follow up during first, third, sixth and one year periods. all parameters noted preoperatively will be measured and noted again. possible statistical difference will be calculated statistically and a cut off value will be seeked.

Eligibility criteria: Inclusion Criteria:

* 18-65 years old
* BMI\>40 kg/m2
* Sleeve gastrectomy operation planned patients

Exclusion Criteria:

* Type 1 or 2 diabetes mellitus
* osteoarticular pathology that may restrict postoperative regular physical activity.
* apparent mental or psychological disorder that may affect postoperative recommendations
* refusal of informed consent for this study

Primary outcomes:
measure: weight loss rates
timeFrame: 6 months
Secondary outcomes:
measure: overall complications
timeFrame: 1 month
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bezmialem Vakif University
Study officials:
affiliation: Bezmialem Vakif University
name: Huseyin K Bektasoglu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06164171: Transesophageal Echocardiography (TEE) and Simulation : a Preferred Learning Path
Official title: Transesophageal Echocardiography (TEE) and Simulation : a Preferred Learning Path
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiac Disease
Keywords: Cardiac disease
Transesophageal echocardiography
TEE
High definition simulator
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-12-11
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1st or 2nd year DESAR interns who participated in the continuing education program

Brief summary: Transesophageal echocardiography (TEE) has gradually become the technique of choice for continuous functional examination of the heart despite the significant training required for its interpretation. It has proven to be the safest, fastest, and most reliable technique for diagnosing most intra- and postoperative hemodynamic problems. Indeed, the transesophageal route is particularly well adapted to the situation of intubated patients, whether in the operating room, in the outpatient department or in intensive care. It offers images that are easier to obtain and of better quality than the transthoracic route; it can be performed without interfering with surgical activity or resuscitation. However, TEE training is often poor during the DES training in anesthesia and resuscitation, reserved for the few interns who will learn in a specific department where TEE is used on a daily basis.

Thus, simulation is a logical and recognized means by which technical aspects, mechanisms involved in the understanding of a situation, reasoning and decision making can be analyzed and improved.

The RFE SFAR 2019 recommendations suggest the use of simulation for the learning of technical gestures in initial training in order to improve their acquisition.

This study is therefore part of a technical and diagnostic improvement of a practice, which appears to be essential in several fields in anesthesia and intensive care, for a technique still not sufficiently acquired by many future practitioners.


Eligibility criteria: Inclusion criteria:

* 1st or 2nd year DESAR interns who participated in the continuing education program
* Interns who agreed to participate in the professional practice evaluation study

Exclusion criteria :

* Interns who did not participate in the training
* Residents who do not agree to take the final test

Primary outcomes:
measure: Ability of a population of medical students to perform a TEE thanks to the contribution of simulation to their learning compared to a population of interns not trained on a high definition simulator Time in seconds required to make the 11 cuts
timeFrame: 1 hour after operation
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Réanimation Chirurgicale - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT03763071: Sleep Disturbances in the 2nd and 3rd Trimester
Official title: Sleep Patterns and Disturbances in the Second and Third Trimester of Uncomplicated Pregnancy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Initiation and Maintenance Disorders
Sleep
Sleep Apnea
Sleep Disorder
Sleep Disturbance
Sleep Apnea, Obstructive
Pregnancy Related
Pregnancy
Lead sponsor: Bartin State Hospital
Sponsor class: OTHER_GOV
First posted: 2018-12-04
Enrollment: 683
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Volunteered, low-risk, uncomplicated singleton pregnancy

Brief summary: Sleep disorders and disturbances are mostly underestimated in clinical practice. Moreover, this problem is generally neglected by the pregnant themselves. Today, it is important to underline any problem that may have an affect to improve the quality of life during pregnancy.

This study assesses the sleep quality, insomnia patterns and obstructive sleep apnea in the second and third trimesters of pregnancy.

Detailed description: Women with uncomplicated pregnancy in the second or third trimester who apply for the routine check will be included.

Specific questionnaires will be used to measure the sleep disorders in addition to the socio-demographic measures:

Pittsburgh Sleep Quality Index, Insomnia Severity Index, Berlin Questionnaire and Stop-Bang Questionnaire.

Eligibility criteria: Inclusion Criteria:

* 2nd or 3rd trimester of pregnancy

Exclusion Criteria:

* Complicated pregnancy
* Multiple pregnancy
* Known sleep disorder

Primary outcomes:
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: Through study completion, an average of 39 weeks
measure: Berlin Questionnaire
timeFrame: Through study completion, an average of 39 weeks
measure: Stop-Bang questionnaire
timeFrame: Through study completion, an average of 39 weeks
measure: Insomnia Severity Index (ISI)
timeFrame: Through study completion, an average of 39 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Bartin
country: Turkey
facility: Bartin State Hospital
Study officials:
affiliation: Bartin State Hospital
name: Murat Yassa, MD
role: PRINCIPAL_INVESTIGATOR
References: